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Purpose: This review provides an update on the
investigations and treatment options for gastroparesis.
Methods: A comprehensive literature search of
Medline, PubMed, Embase and OVID was conducted
which included all systematic reviews and research
articles that focused on the diagnosis, investigations
and management diabetic gastroparesis.
Findings: Dietary modiﬁcations and pharmacologic
treatment with prokinetics to increase gastric motility
form the mainstay of treatment. However, the use of
prokinetics is limited by adverse effects and serious
adverse effects, leaving metoclopramide as the only drug
approved by the US Food and Drug Administration for
the treatment of gastroparesis. Newer therapies, includ-
ing motilin receptor agonists, ghrelin receptor agonists,
and neurokinin receptor antagonists, are currently being
investigated. Transpyloric stenting, gastric electrical
stimulation, and gastric per-oral endoscopic myotomy
provide mechanical options for intervention, and surgi-
cal interventions in severe intractable gastroparesis
include laparoscopic pyloroplasty or gastrectomy.
Implications: Advances to better understand the
pathophysiology and management of diabetic gastro-
paresis have been limited, especially with discordance
between symptoms and severity of delay in gastric
emptying. Established treatment options are limited;] 2018however, recent pharmacologic and surgical interven-
tions show promise. (Clin Ther. 2018;]:]]]–]]]) &
2018 Elsevier HS Journals, Inc. All rights reserved.
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First described by Rundles in 1945,1 the term
gastroparesis diabeticorum was coined by Kassander
in 1958.2 The most common cause of gastroparesis, a
condition characterized by delayed gastric emptying in
the absence of a mechanical obstruction, is diabetes
mellitus.3,4 This condition can manifest in a variety of
symptoms, including early satiety, nausea, vomiting,
and anorexia. It can be associated with signiﬁcant
morbidity and impaired quality of life, with anxiety
and depression and an effect on patients’ self-manage-
ment of diabetes, especially with ﬂuctuating glucose
levels.5,6 However, the association between the se-
verity of symptoms and delay in gastric emptying is
not linear.7 Indeed, up to 40% of patients with1
Clinical Therapeuticsdiabetic gastroparesis (DG) can be asymptomatic.8
The term gastric hypoglycemia has been used to
describe patients with hypoglycemia attributable to
gastroparesis, and it should be considered in the
differential diagnosis for patients diagnosed as
having brittle diabetes.9,10 A comprehensive literature
search of Medline, PubMed, Embase and OVID was
conducted which included all systematic reviews and
research articles that focused on the diagnosis, inves-
tigations and management of diabetic gastroparesis.EPIDEMIOLOGY
The exact prevalence of DG remains unknown. A major
population-based study, evaluating symptoms, reported
a 10-year cumulative incidence of gastroparesis of 5.2%
in patients with type 1 diabetes mellitus (T1DM), 1.0%
in patients with type 2 diabetes mellitus (T2DM), and
0.2% in controls.11 The T1DM Exchange registry data
reported 4.8% of patients had gastroparesis, with
signiﬁcant associations with female sex, longer duration
of diabetes, older age, and more frequent severe
hypoglycemic episodes, despite higher glycosylated
hemoglobin (HbA1c) levels.
12 Although less common
than in patients with T1DM, the greater prevalence of
T2DM means that more patients have gastroparesis
attributable to this condition.8 There are conﬂicting
data on the prevalence of symptoms of gastroparesis in
patients with diabetes.13,14 In addition to delayed gastric
emptying, patients may also develop rapid gastric empty-
ing, with one study reporting this phenomenon in 22%
of patients evaluated with scintigraphy.15
An interesting phenomenon is that of symptom turn-
over (the appearance and disappearance of symptoms
over time), and several studies found this to be common
in patients with DG. One study remarked that the
turnover of symptoms was associated with depression
rather than other factors, such as glycemic control.16,17PATHOPHYSIOLOGY
The effective movement of gastric contents through the
stomach depends on 2 major activities: peristalsis of
gastric smooth muscle propelling contents to the pylo-
rus and dilation of the pyloric sphincter. Interstitial cells
of Cajal (ICCs) are specialized pacemaker cells that
drive the contraction of gastric smooth muscle. The
speed, strength, and, to a lesser degree, frequency of
these contractions are known to be modiﬁed by both
neurologic and neuroendocrine modulation.2Gastroparesis is deﬁned as the delayed removal of
stomach contents in the absence of a physical obstruc-
tion.18 Hyperglycemia mediates nerve damage through
a wide range of mechanisms, including poly–adenosine
triphosphate ribose, advanced glycosylation end (AGE)
products, endoplasmic reticulum stress, oxidative stress,
inﬂammation, and ischemia,19,20 which result in demye-
lination and axonal degeneration.21,22 Neuropathy,
affecting autonomic input, such as from the vagus
nerve, or that affecting the enteric nervous system’s
own intrinsic neurons, can induce gastroparesis. Loss of
parasympathetic stimulation will slow gastric emptying,
a picture mimicked during surgical vagotomy.23
Extensive myelinated and unmyelinated nerve ﬁber
and endoneurial capillary pathologic ﬁndings have
been found in the vagus nerve of diabetic patients
with severe gastroparesis, although interestingly this
was comparable to 2 diabetic patients without
gastroparesis.24 Both direct neurologic feedback from
the small bowel and hormones, such as cholecystokinin
and gastric inhibitory peptide, can limit the ﬂow of
chyme into the duodenum. Abnormalities of gastric
electrical rhythm and transmission can lead to a
disruption of the migrating motor complex, ineffective
propulsion, and decreased pyloric output.25,26 The
severity of these arrhythmias has been directly linked
to loss of ICCs, although not to the severity of
symptoms.27 The origin of gastroparesis has therefore
been related to the pathologic features of the ICCs and
vagal neurons.28,29
Neural nitric oxide synthase (nNOS) expressed in
gastric neurons induces relaxation and accommoda-
tion, although its predominant function is to cause
dilatation of gastrointestinal sphincters, including the
pylorus.29 In animal models of DG, reduced nNOS
mRNA, protein, and function30 restricts the passage
of food into the duodenum. Interestingly, the
reduction in nNOS is not attributable to a loss of
active neurons but decreased expression on these
intrinsic neurons.8
A signiﬁcant decrease in ICC counts has been found
in gastric biopsy specimens of patients with gastro-
paresis.31–34 Interestingly, biopsy specimens of pa-
tients with gastroparesis-like syndrome (no evidence
of delayed gastric emptying) reveal signiﬁcantly lower
ICC counts,35 emphasizing their critical importance to
gastroparesis. Indeed, a decreased ICC count is a key
histologic ﬁnding in gastroparesis.29 Unlike diabetic
neuropathy where the deleterious effects stem fromVolume ] Number ]
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ICC counts is related to the body’s response to this
condition. Murine models indicate that hyperglycemia
per se is not the cause of decreased ICC counts but
rather a decrease in the quantity or sensitivity to
insulin and insulin-like growth factor.36,37
Murine models using streptozotocin diabetes show
a decrease in ICC density and a delay in gastric
emptying.38 However, when streptozotocin was
given to mice that genetically lacked Csf1, a factor
essential for the development of macrophages in
gastrointestinal musculature, the effect on ICCs and
emptying was lost,39 suggesting a potential role for
macrophage-mediated induction of DG. Gastric
macrophages differentiate and are classed as M1, a
proinﬂammatory phenotype, or M2, an anti-
inﬂammatory phenotype.40 Murine gastroparesis
models relatively express larger populations of M1
compared with M2.41 The presence of the M2
phenotype has been found to protect against
gastroparesis in mice through a potent antioxidant,
heme oxygenase 1–dependent process.42 Up-
regulation of heme oxygenase 1 by hemin, a process
reproducible in humans, reverses the loss of ICCs,
gastric motility, and nNOS in animal models of DG.42
In patients with gastroparesis, a loss of CD206þ
macrophages of the M2 phenotype in the gastric
antrum is related to the ICC density.41 Recent
studies show that insulin and insulin-like growth
factor 1 can affect macrophage function by
promoting inﬂammation,43–45 which may explain
how these factors contribute to ICC loss.
Pharmacologic management of diabetes may also
affect gastric motility. Endogenous glucagon-like pep-
tide 1 slows gastric emptying46; therefore, exogenous
glucagon-like peptide 1 analogues and dipeptidyl
peptidase 4 inhibitors could theoretically delay
gastric emptying. However, clinical studies have not
found any effect of these therapies on gastric
emptying.47–49INVESTIGATIONS
The diagnosis of gastroparesis entails the exclusion
of a mechanical obstruction, typically with an
oesophagogastroduodenoscopy or barium meal.
The gold standard for diagnosis is scintigraphy,
although breath testing and the SmartPill have been
developed as alternatives. Other modalities, such as] 2018ultrasonography, magnetic resonance imaging, and
electrogastrography, are much less commonly used.
Gastric-emptying scintigraphy
There has been an attempt to standardize test
protocols using gastric-emptying scintigraphy.50 A
standard low-fat meal is used, although this can be
combined with an isotope-labeled liquid. Although a
delay in liquid emptying may not be apparent until the
development of severe gastroparesis, the sensitivity for
detecting gastroparesis may be improved if there is
delayed liquid emptying in the presence of normal
solid emptying.51–53 After an overnight fast, a stand-
ard, low-fat, radiolabeled meal is ingested within 10
minutes, and imaging is performed at baseline and 1,
2, and 4 hours with the patient in a standing position.
Glucose level should be o275 mg/dL, and use of
drugs that affect gastric emptying needs to be discon-
tinued before the procedure. Delayed gastric emptying
is deﬁned by 460% retention at 2 hours or 410%
retention at 4 hours. A major consideration for this
form of imaging is that females can have a physiologic
delay in gastric emptying of approximately 15%.
Additional pitfalls include intraindividual variation
of gastric emptying of up to 24%, and the use of an
abnormal low-fat, low-ﬁber meal that may not mimic
real-life meals and thereby lower sensitivity.54
Gastric Emptying Breath Test
The gastric emptying breath test relies on the use of a
radiolabeled carbon-containing test meal (carbon 13–
labeled S platensis or octanoic acid). A similar prepa-
ration to gastric-emptying scintigraphy is needed for
this investigation. The radiolabeled carbon is released
during digestion, and the carbon dioxide is released by
respiration through ventilation is measured 4 to 6 hours
later. Any exertion that results in increased ventilation
rate needs to be avoided.54,55 This investigation may be
as accurate as gastric-emptying scintigraphy.56
Wireless motility capsule
The SmartPill can evaluate pH, pressure, and temper-
ature in addition to whole gut transit time. Data are
transmitted directly to a portable receiver. The SmartPill
is ingested with a standard meal after use of acid-
suppressing medications have been discontinued. Move-
ment of the capsule from an acidic to an alkaline
environment represents transit from the stomach to
the duodenum, normally within 5 hours. The use of this3
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Clinical Therapeuticsdiagnostic modality allows for ambulatory assessment
of patients, is radiation free, and may also provide
additional physiologic information.54MANAGEMENT
The general principles of management are to restore
nutritional and hydration status, alleviate symptoms,
and stabilize diabetes control. The Figure shows an
approach to investigations and management.
Dietary Modifications
In conjunction with improving nutrition, ﬂuid and
electrolyte balance also needs to be corrected. Correc-
tion of prolonged poor nutrition may predispose
patients to refeeding syndrome. Multiple small meals
(4 to 6 per day) are preferred to fewer large ones.
Meals should be low in fat and ﬁber because these can
slow gastric emptying.57–59 Smoking and alcohol
consumption may also delay gastric emptying and
should be avoided.60,61 A trial of 56 patients with DG
found that a small particle size diet may alleviate
symptoms.62 High-calorie liquid drinks may also be a
useful adjunct to the management of gastroparesis.
Certain foods, such as pizza, orange juice, coffee,
broccoli, salsa, and roast beef, which fall into the
categories of spicy, acidic, fatty, and high ﬁber and
may delay gastric emptying, should be limited or
excluded.63
When oral nutrition is not possible or inadequate,
assisted nutrition should be considered. The enteral
route is preferable to parenteral nutrition when
possible because of the lower risk of complications,4such as line infection and thrombosis. A nasojejunal
tube may be used initially, followed by a jejunostomy
tube, if required.59
Glycemic control
The association between glycemic control and
gastroparesis is not fully understood and, of course,
may be bidirectional. Earlier studies found that acute
hyperglycemia delayed gastric emptying in healthy
individuals.64,65 Subsequent studies found that in
people with T1DM, hyperglycemia prolonged gastric
emptying of solids and liquids,66–68 with reduced
antral mobility and increased proximal gastric adher-
ence.67,69 In contrast, acute hypoglycemia accelerates
gastric emptying in healthy controls.70 Paradoxically,
in patients with T2DM, a higher fasting blood
glucose level was associated with faster gastric
emptying.71,72
There are conﬂicting data on the effect of long-
term glycemic control on gastric emptying, with
several studies having previously found no correla-
tion in patients with T2DM and T2DM.71,73–75
However, recently, in a follow-up cohort of 78
patients from the Diabetes Control and Complica-
tions Trial/Epidemiology of Diabetes Interventions
and Complications studies who underwent an assess-
ment of gastric emptying using the breath test, base-
line HbA1c level, duration of diabetes, and mean
HbA1c level during the trial period were associated
with delayed gastric emptying.76 A further
retrospective study of patients with diabetes who
had undergone gastric-emptying scintigraphy found
that a higher HbA1c level was signiﬁcantly associated
with higher gastric retention at 4 hours.77PHARMACOLOGIC TREATMENT
Prokinetics, used to promote gastrointestinal tract
motility, have been and remain the mainstay of treat-
ment for gastroparesis (Table).78 However, data are
lacking on the long-term effectiveness of these drugs,
perhaps also reﬂecting the varying clinical course of
this condition whereby long-term treatment is often
not necessary.7
Metoclopramide
Metoclopramide is a potent dopamine D2 receptor
antagonist and serotonin (5HT4) receptor agonist that
acts on the brainstem and peripheral nerves. In theVolume ] Number ]
Table. Pharmacological treatment options for the management of diabetic gastroparesis.
Class of Medication Effect on GI Tract Use in Diabetic Gastroparesis
Dopamine D2 receptor
antagonists
(metoclopramide,
domperidone)
Increases contractions of the gastric
antrum by releasing acetylcholine
from enteric neurons
Metoclopramide is FDA
approved for diabetic
gastroparesis. Domperidone
may avoid CNS adverse
effects.
Motilin receptor agonists
(erythromycin, mitemcinal,
and camicinal)
Increased antral contraction Erythromycin favored in extremely
unwell, hospitalized patients, risk of
tachyphylaxis with erythromycin
5HT4 receptor agonists
(cisapride, tegaserod,
revexepride)
Increased muscular contraction via
cholinergic pathways
Older agents not used due to cardiac
safety concerns, more selective agents
undergoing evaluation
Ghrelin receptor agonists (TZP
101, TZP 102, relamorelin)
Increased migrating motor
complexes (Phase III) and vagal
signaling.
Signiﬁcant improvement in symptoms in
clinical trials
Neurokinin receptor antagonists
(aprepitant)
Antiemetic, antagonizes the effects
of substance P
Limited trial data
CNS ¼ central nervous system; FDA ¼ US Food and Drug Administration; GI ¼ gastrointestinal.
M. Kumar et al.gastrointestinal tract, it increases contractions of the
gastric antrum by releasing acetylcholine from enteric
neurons.79–81 The central effects may account in some
part for the reduction of nausea. An early double-blind,
placebo-controlled trial of 40 patients with DG found
that metoclopramide 10 mg QID PO produced a
signiﬁcant improvement in meal tolerance, symptoms of
gastroparesis, and gastric emptying during 3 weeks.82 In
a subsequent double-blind, placebo-controlled study of
13 patients with DG, metoclopramide was administered
parenterally and then orally before each meal and before
bed and produced a mean symptom reduction of 52.6%
and improved gastric emptying in 7 patients.83 It remains
the only drug approved by the US Food and Drug
Administration (FDA) for the treatment of
gastroparesis. However, concerns regarding potentially
irreversible tardive dyskinesia has led to an FDA warning
restricting its use to no longer than 3 months and
recommendations to use the lowest effective dose for
the shortest possible time. Indeed, along with older age
and female sex, diabetes itself is a risk factor for
developing tardive dyskinesia.81] 2018Domperidone
Domperidone, another dopamine D2 receptor antag-
onist, does not cross the blood brain barrier and
therefore does not cause the same central nervous
system adverse effects.84 A dose of 10 mg TID
improves a range of gastroparesis-related symptoms.85
This drug is not currently FDA approved, and its
prescription in the United States requires an
investigational new drug application because of the
risk of QTc prolongation and cardiac arrhythmias.
Motilin Receptor Agonists
Erythromycin is a macrolide antibiotic that ago-
nizes motilin receptors, leading to increased antral
contraction.86 The intravenous route is strongly
favored in hospitalized patients, although
tachyphylaxis may occur with this drug usually after
4 weeks of use.87 There are potential interactions with
other drugs because of cytochrome P450 C3A4
inhibition. Clarithromycin and azithromycin have
also been used, but there is a paucity of supporting
clinical trial data. A retrospective case-control analysis5
Clinical Therapeuticsof 120 patients found equal efﬁcacy between
azithromycin and erythromycin in accelerating
gastric emptying in gastroparesis.88 A smaller study
that evaluated intravenous use of erythromycin and
azithromycin found similar stimulation of antral
activity with a longer duration of effect.89 The
advantages of azithromycin are the lack of P450
inhibition, longer duration of action, and better
adverse effect proﬁle; however, more research needs
to be performed to investigate its utility further.
Macrolides can also cause QTc prolongation
through their effect on IKr potassium channels.
90
New agents acting on the motilin receptor, includ-
ing mitemcinal and camicinal, deliver the beneﬁts of
treatment without the antibiotic activity reducing the
risk of tachyphylaxis. However, a double-blind, pla-
cebo-controlled trial of mitemcinal found no symptom
relief compared with placebo despite an improvement
in gastric emptying.91 A single dose of camicinal in
patients with T1DM signiﬁcantly accelerates gastric
emptying of solids, and further trials are under way.92
5HT4 Receptor Agonists
The 5HT4 receptor agonist class of drugs activate
5HT4 receptors, leading to increased muscular con-
traction via cholinergic pathways.93 Cisapride, a
5HT4 receptor agonist and established drug for
gastroparesis, was withdrawn because of cardiac
safety concerns attributable to activation of hERG
potassium channels, leading to QTc prolongation and
ventricular arrhythmias. Similarly, tegaserod, another
5HT4 agonist, has been withdrawn because of cardiac
safety concerns.94 Recently, more selective 5HT4
receptor agonists have been developed, but a trial of
revexepride in patients with gastroparesis found no
beneﬁt on symptoms or gastric emptying versus
placebo.95
Ghrelin Receptor Agonists
Ghrelin is a peptide released from gastric mucosal
endocrine cells.96 Stimulation of the GHS-R1a
receptor results in increased migrating motor
complexes (Phase III) and vagal signaling.97,98 Four
single daily intravenous infusions of TZP 101 (uli-
morelin) were associated with a signiﬁcant improve-
ment in symptoms of gastroparesis up to 30 days after
administration in 23 patients with DG compared with
placebo.99 In a Phase IIa trial of 92 patients with DG,
TZP 102, an oral ghrelin receptor agonist, produced a6signiﬁcant improvement in symptoms during 28
days.100 A subsequent Phase IIb study of TZP 102
in 201 patients with DG found signiﬁcant symptom
improvement but failed to establish efﬁcacy compared
with placebo.101 Recently, relamorelin, a
subcutaneously administered ghrelin agonist, also
produced a signiﬁcant improvement in vomiting and
gastric emptying compared with placebo in patients
with DG.102Neurokinin Receptor Antagonists
Substance P is a peptide involved in the induction
of vomiting, with actions through binding to neuro-
kinin 1 receptors.103 Aprepitant is an neurokinin 1
receptor antagonist that is currently widely used in
chemotherapy-induced vomiting and nausea.
Fountoulakis reported 2 cases of DG that were
successfully treated with aprepitant for 12 and 18
months.104 There are currently no published trials of
this drug for DG.OTHER THERAPIES
Botulinum Toxin
A manifestation of DG is pylorospasm, and botu-
linum toxin, which blocks acetylcholine release at the
neuromuscular junction and reduces excessive pyloric
contraction, has been evaluated.105–107 Initial case
series showed an improvement in symptoms and
gastric emptying108–110; however, 2 small randomized
controlled trials have not yielded positive re-
sults,111,112 questioning the efﬁcacy of this treatment
in gastroparesis.113 Furthermore, a retrospective
analysis of 179 cases treated with botulinum toxin
suggested that diabetes further limited a beneﬁt.114Transpyloric Stenting
Endoscopic stent placement has been investigated
in small series of patients with gastroparesis. Khashab
et al115 reported their experience in 30 patients
undergoing a total of 48 procedures. Although the
data were incomplete, there were reports of symptom
improvement and more rapid gastric emptying, but
stent migration is a complication. The authors
suggested that transpyloric stenting may be a useful
salvage therapy or may help identify patients who
may beneﬁt from other therapies directed at the
pylorus.Volume ] Number ]
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Gastric electrical stimulation treatment has been
approved by the FDA and the National Institute for
Health and Care Excellence for the treatment of drug
refractory DG. A device implanted into the abdominal
wall has leads that extend into the greater curvature of
the stomach and generates 12 pulses per minute. Abell
et al116 studied 38 patients undergoing gastric
electrical stimulation and found a reduction in
symptoms with associated weight gain. Long-term
follow-up has reported morbidity reduction for up
to 10 years after the procedure.116,117 Heckert et al118
reported an improvement in symptoms in 75% of 151
patients undergoing this procedure, and patients with
diabetes surprisingly had greater success.
Gastric Per-Oral Endoscopic Myotomy
Khashab et al119 reported an improvement in
symptoms in 26 of 30 patients undergoing gastric
per-oral endoscopic myotomy for refractory
gastroparesis. However, in patients undergoing this
procedure for mechanical obstruction, there was a
high rate of dumping syndrome with postprandial
hypoglycemia, but this appears less common in
patients with gastroparesis.120SURGICAL TREATMENTS
A number of treatments have been used in severe
intractable gastroparesis. Laparoscopic pyloroplasty
was evaluated retrospectively in 46 patients and
revealed a signiﬁcant symptom improvement and
gastric emptying in 90% of cases.121 Gastrectomy
has also been used in selected patients to alleviate
severe refractory symptoms, may be considered in
those with high risk of renal failure or premature
death,122–124 and may be considered earlier in patients
with failed GES.125 Pancreatic transplantation may be
of beneﬁt in DG, perhaps in the short term via
improved glycemic control and in the long term
through nerve ﬁber regeneration.126,127APPROACH TO THE MANAGEMENT OF
GASTROPARESIS
The American College of Gastroenterology guidelines
recommend that a documented delay in gastric empty-
ing is required for the diagnosis, with scintigraphy
being the most reliable gold standard.113 Other
alternatives still require further validation for use in] 2018the diagnosis of DG. Before undertaking any
investigation, use of all medications that have the
potential to affect gastric emptying must be stopped
for at least 48 hours. These medications include
narcotic opioid analgesics and anticholinergic agents
(may give a falsely delayed result) or the medications
metoclopramide, domperidone, and erythromycin
(which accelerate gastric emptying and may give a
falsely normal result). Hyperglycemia can lead to a
deterioration in symptoms, so glycemic control should
be measured and improved before testing during any
gastric emptying studies.
Primarily, the management of DG is ensuring
hydration, adequate electrolytes, and nutritional sup-
port. One of the main themes of any guidelines on
gastroparesis is the importance of optimizing glycemic
control. Dietician input should be sought with regard
to the consumption of frequent small-volume meals
low in fat and soluble ﬁber. The guidelines suggest
that indications for enteral nutrition include uninten-
tional loss of ≥10% of usual weight during 3 to 6
months and/or repeated admission for refractory
symptoms. A nasogastric tube should be used initially,
followed by a jejunostomy if indicated. This approach
may reduce hospital admissions and improve
symptoms.128
The strongest evidence and recommendations are
with metoclopramide as the ﬁrst line of prokinetic
therapy, which should be given at the lowest effective
dose in liquid formation to facilitate absorption. It is
approved for a duration of 12 weeks, and advice
should be given to discontinue therapy if patients
develop adverse effects, such as tardive dyskinesia. If
patients do not tolerate metoclopramide, then dom-
peridone can be used with investigational new drug
clearance from the FDA. Domperidone does not have
the predisposition for central nervous system adverse
effects as metoclopramide does; however, there is a
tendency for this to cause a prolonged QTc in interval,
so a baseline ECG in recommended. If the QTc is
4470 msec in men and 450 msec in women, then this
should be withheld. A follow-up ECG while the
patient is receiving domperidone treatment is advised.
The use of erythromycin orally and intravenously in
hospital when intravenous prokinetic therapy is ini-
tiated is recommended.
The surgical procedures mentioned earlier may be
considered on an individual basis in refractory cases.
In patients in whom nausea and vomiting are an issue,7
Clinical Therapeuticsantiemetics should be considered for symptomatic
treatment, and in refractory cases, tricyclic antidepres-
sants can be used; however, caution must be taken
they may retard gastric emptying. The National
Institute for Health and Care Excellence guidelines
advise that gastric electrical stimulation is an option
patients with chronic, intractable nausea and vomit-
ing, and its use in particular is beneﬁcial in DG.129CONCLUSION
DG remains a challenging complication of diabetes.
Advances in understanding the pathophysiology of
this condition have been limited. The management of
gastroparesis is difﬁcult because there is discordance
between symptoms and the degree of delayed gastric
emptying. Because of the relatively low prevalence of
DG and the ﬂuctuating symptoms, it is often difﬁcult
to recruit patients into clinical trials. Current treat-
ment options are limited; however, recent pharmaco-
logic and endoscopic interventions show promise.CONFLICTS OF INTEREST
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